Wainstein, 20183434. Wainstein C, Quera R, Fluxá D, Kronberg U, Conejero A, López-Köstner F, et al. Stem Cell Therapy in Refractory Perineal Crohn’s Disease: Long-term Follow-up. Colorectal Dis. 2018. doi: 10.1111/codi.14002. https://doi.org/10.1111/codi.14002...
|
Cohort |
Adipose-Mesenchymal Stem Cells. |
Describe long-term outcomes of patients with perineal Crohn’s disease who received combined treatment with ASCs, platelet-rich plasma and endorectal advancement flaps. |
Female=7 |
All complex fistula |
L1=1 |
7.4 (4-15) |
10/11 (91%) fistulas were completely healed and 1/11 (9%) was partially healed. |
Not described |
|
|
|
|
Male=2 |
|
L2=1 |
|
|
|
|
|
|
|
Total=9 |
|
L3=6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Age=38.6 (23-57) |
|
|
|
|
|
Dige, 20193535. Dige A, Hougaard HT, Agnholt J, Pedersen BG, Tencerova M, Kassem M, et al. Efficacy of Injection of Freshly Collected Autologous Adipose Tissue Into Perianal Fistulas in Patients With Crohn’s Disease. Gastroenterology. 2019;156:2208-2216.e1. doi: 10.1053/j.gastro.2019.02.005. https://doi.org/10.1053/j.gastro.2019.02...
|
Cohort |
Autologous Adipose Tissue. |
Complete fistula healing after 6 months. |
Female=15 |
Transsphincteric (n=13) |
- |
- |
12 (57%) patients had complete fistula healing on clinical examination 6 months after 1 (n=9), 2 (n=2) or 3 (n=1) injections with adipose tissue. |
Not described |
|
|
|
|
Male=6 |
Anovaginal (n=7) |
|
|
|
|
|
|
|
|
Total=21 |
High intersphincteric (n=1). |
|
|
|
|
Serrero, 20193636. Serrero M, Grimaud F, Philandrianos C, Visée C, Sabatier F, Grimaud JC. Long-term Safety and Efficacy of Local Microinjection Combining Autologous Microfat and Adipose-Derived Stromal Vascular Fraction for the Treatment of Refractory Perianal Fistula in Crohn’s Disease. Gastroenterology. 2019;156:2335-37.e2. doi: 10.1053/j.gastro.2019.01.032. https://doi.org/10.1053/j.gastro.2019.01...
|
Cohort |
Autologous Microfat and Adipose-Derived Stromal Vascular Fraction. |
Fechamento das fístulas. |
Female=4 |
Intersphincteric=1 |
- |
8 (2-38) |
Seventy percent of patients had a clinical response at week 12, and 80% at week 48; 20% and 60% of patients achieved combined remission at weeks 12 and 48, respectively. In addition, 13 of 17 treated external openings showed complete re-epithelialization or an absence of drainage at week 48. Two patients showed complete occlusion of fistula tracts on magnetic resonance imaging at week 48. |
Not described |
|
|
|
|
Male=6 |
Trans sphincteric=8 |
|
|
|
|
|
|
|
|
Total=10 |
Extrasphincteric=1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Age=36 (19-63) |
|
|
|
|
|
Brunner, 20193737. Brunner M, Schneider I, Günther K, Grützmann R, Matzel KE. Permacol™ collagen paste for cryptoglandular and Crohn’s anal fistula. Tech Coloproctol. 2019;23:135-141. doi: 10.1007/s10151-019-01932-z. https://doi.org/10.1007/s10151-019-01932...
|
Cohort |
Permacol™ collagen paste. |
Assess the use of Permacol™ collagen paste. |
Female=9 |
Trans sphincteric=10 |
- |
- |
The healing rate in all patients was 57% at 6 months and 63% at 12 months. One patient reported a worsening of fecal incontinence at 12 months; two patients had adverse events requiring fistula drainage. |
Not described |
|
|
|
|
Male=3 |
Retovaginal=2 |
|
|
Patient characteristics, healing, incontinence, and adverse events did not differ significantly between patients with and without Crohn’s disease. |
|
|
|
|
|
Total=12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Age=33 [17-78] |
|
|
|
|
|
Löwenberg, 20193838. Löwenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, et al. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease. Gastroenterology. 2019;157:997-1006.e6. doi: 10.1053/j.gastro.2019.05.067. https://doi.org/10.1053/j.gastro.2019.05...
|
Cohort |
Vedolizumab. |
Ability of vedolizumab to induce endoscopic and histologic remission in patients with Crohn’s disease. |
Female=77 |
Not described |
L1=26 |
9 (5-16) |
3 of 9 patients closed the fistulas. |
Not described |
|
|
|
|
Male=33 |
|
L2=32 |
|
|
|
|
|
|
|
Total=110 |
|
L3=50 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fistula=9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Age=36 (28-46) |
|
|
|
|
|
Herreros, 20193939. Herreros MD, Garcia-Olmo D, Guadalajara H, Georgiev-Hristov T, Brandariz L, Garcia-Arranz M. Stem Cell Therapy: A Compassionate Use Program in Perianal Fistula. Stem Cells Int. 2019;2019:6132340. doi: 10.1155/2019/6132340. https://doi.org/10.1155/2019/6132340...
|
Cohort |
Autologous Mesenchymal Stem Cells. |
To report experience in a compassionate use program for complex perianal fistula. |
Female=21 |
18 Crohn’s-associated fistula-in-ano. |
- |
- |
100% showed healing or improvement/ partial response, starting in a mean time of 5.3 weeks (range: 2-12 weeks). Healing was found in 10/18 (55.5%) cases. Most of them were cured in a meantime of 6.5 months (range: 0.5-24 months). |
Not described |
|
|
|
|
Male=24 |
|
|
|
|
|
|
|
|
|
Total=45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Age=45 (29-69) |
|
|
|
|
|
Biemans, 20204040. Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, Löwenberg M, Dijkstra G, Oldenburg B, et al. Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis . 2020;14:33-45. doi: 10.1093/ecco-jcc/jjz119. https://doi.org/10.1093/ecco-jcc/jjz119...
|
Cohort |
Ustekinimab. |
Corticosteroid-free clinical remission. |
Female=133 |
Not described |
L1=68 |
12.3 [7.5-19.3] |
35.7% resolved fistulas within 24 weeks. |
Significant subgroups: BMI, upper gastrointestinal involvement, perianal fistula, anti-integrin exposure, moderate to severe activity. |
|
|
|
|
Male=88 |
|
L2=76 |
|
|
|
|
|
|
|
Total=221 |
|
L3=77 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Age=38.2 [29.3-52.2] |
|
Perianal disease=37 |
|
|
|
Chapuis-Biron, 20204141. Chapuis-Biron C, Bourrier A, Nachury M, Nancey S, Bouhnik Y, Serrero M, et al. Vedolizumab for perianal Crohn’s disease: a multicentre cohort study in 151 patients. Aliment Pharmacol Ther . 2020;51:719-27. doi: 10.1111/apt.15665. https://doi.org/10.1111/apt.15665...
|
Cohort |
Vedolizumab. |
No draining fistula at clinical examination and no anal ulcers for primary lesions at 6 months without medical or surgical treatment for perianal Crohn’s disease. |
Female = 69 |
Primary = 23 |
L1 = 11 (10.8) |
14.6 (7) [2-36] |
Vedolizumab success in 23/102 patients with active perianal disease, dos com seton 9/61. |
Factors associated with success were the number of prior biologic agents (≥3, odds ratio, OR: 0.13, 95%CI) and no antibiotics at initiation (OR: 4.12, 95%CI). |
|
|
|
|
Male = 33 |
secondary lesions |
L2 = 34 (33.3) |
|
|
|
|
|
|
|
Total = 102 |
(fistulas, rectovaginal fistulas and abscesses) = 96 |
L3 = 57 (55.9) |
|
|
|
|
|
|
|
|
Tertiary = 17 |
L4 = 17 (16.7) |
|
|
|
|
|
|
|
Age = 38.9 (10.8) [21-63] |
|
|
|
|
|